Business Context and Reporting Period
Company: Omeros Corporation (OMER)
Filing Type: Form 8-K (Current Report)
Report Date: November 9, 2021
Reporting Period: This filing announces financial results for the three and nine months ended September 30, 2021. The specific financial data is contained in a press release furnished as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details regarding material changes versus prior periods. It solely serves to notify the market of the issuance of the Q3 2021 financial results press release.
Guidance, Outlook, and Risks
Management Commentary: The report was signed by Gregory A. Demopulos, M.D., President, CEO, and Chairman of the Board.
Legal Disclaimer: The filing explicitly states that the information contained herein, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to liability under that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933. Furthermore, this information shall not be incorporated by reference into any other SEC filing by the company.
Guidance and Risks: No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net loss, and cash position figures for the three and nine months ended September 30, 2021.
- Verify the company's cash runway and burn rate, as these are critical for a clinical-stage biopharmaceutical company.
- Check for updates on clinical trial progress for the company's lead drug candidates, which are typically discussed in the accompanying press release.
- Confirm the status of any recent financing activities or debt obligations not detailed in this cover sheet.